Analyst Soumit Roy from JonesTrading reiterated a Buy rating on Adicet Bio and increased the price target to $5.00 from $4.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Soumit Roy’s rating is based on the promising outcomes from Adicet Bio’s off-the-shelf cell therapy, which provides a competitive edge in the market. The recent positive data from their CD20 targeting CAR γδ T cells (ADI-001) in lupus nephritis and systemic lupus erythematosus demonstrated efficacy comparable to peers, with a potentially superior safety profile. This off-the-shelf benefit distinguishes Adicet from other programs, making it an attractive investment.
Furthermore, the initial Phase 1 data showed significant clinical responses, including complete renal responses in lupus nephritis patients and rapid reductions in disease activity scores. The treatment was well tolerated, with no severe adverse events reported. Adicet’s strong cash position and strategic plans to initiate pivotal trials further support the Buy rating, as the company is well-positioned to advance its pipeline and capitalize on its innovative therapies.
Roy covers the Healthcare sector, focusing on stocks such as Protara Therapeutics, CervoMed, and aTyr Pharma. According to TipRanks, Roy has an average return of -19.0% and a 24.09% success rate on recommended stocks.